Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares fell 4.1% during trading on Thursday . The stock traded as low as $4.40 and last traded at $4.48. 10,987 shares were traded during mid-day trading, an increase of 407% from the average session volume of 2,165 shares. The stock had previously closed at $4.67.
Graybug Vision Price Performance
The firm’s fifty day simple moving average is $4.73 and its 200 day simple moving average is $4.80. The company has a market capitalization of $7.09 million, a price-to-earnings ratio of -0.18 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Articles
- Five stocks we like better than Graybug Vision
- 3 Small Caps With Big Return Potential
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Are Dividend Contenders? Investing in Dividend Contenders
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Insider Trading – What You Need to Know
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
